Artelo Biosciences (NASDAQ:ARTL) Upgraded at LADENBURG THALM/SH SH

LADENBURG THALM/SH SH upgraded shares of Artelo Biosciences (NASDAQ:ARTL) to a strong-buy rating in a research report released on Wednesday morning,Zacks.com reports.

Several other analysts also recently issued reports on ARTL. EF Hutton Acquisition Co. I raised shares of Artelo Biosciences to a “strong-buy” rating in a research note on Tuesday, October 1st. D. Boral Capital reissued a “buy” rating and set a $6.00 price target on shares of Artelo Biosciences in a research note on Monday, December 9th. Finally, HC Wainwright restated a “buy” rating and set a $5.00 price objective on shares of Artelo Biosciences in a report on Monday, December 9th.

Artelo Biosciences Stock Performance

NASDAQ:ARTL opened at $1.06 on Wednesday. The firm has a market capitalization of $3.42 million, a PE ratio of -0.37 and a beta of 1.29. The stock’s fifty day moving average is $1.11 and its 200 day moving average is $1.21. Artelo Biosciences has a fifty-two week low of $0.91 and a fifty-two week high of $1.75.

Artelo Biosciences (NASDAQ:ARTL) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.06. Equities analysts forecast that Artelo Biosciences will post -2.62 EPS for the current year.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.